Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine

Biochimica et Biophysica Acta - Biomembranes

Volumn 1848, Issue 11, 2015, Pages 2918-2931

  Riedl, Sabrina ^a   Leber, Regina ^a   Rinner, Beate ^b   Schaider, Helmut ^b,c   Lohner, Karl ^a,d   Zweytick, Dagmar ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d BIOTECHMED GRAZ   (Austria)

Author keywords

Antitumor peptides; Apoptosis; Glioblastoma; Melanoma; Phosphatidylserine; Targeted therapy

Indexed keywords

CASPASE 3; CASPASE 7; CHONDROITIN SULFATE; HEPARIN; LACTOFERRICIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; SIALIC ACID; DIPEPTIDE; LACTOFERRICIN B; LACTOFERRIN; LIPID BILAYER; MEMBRANE LIPID;

ALPHA HELIX; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL KILLING; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; GLIOBLASTOMA CELL LINE; MELANOMA CELL; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PROTEIN INTERACTION; RHABDOMYOSARCOMA CELL; SEQUENCE ANALYSIS; STATIC ELECTRICITY; ZETA POTENTIAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL MEMBRANE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CIRCULAR DICHROISM; DIFFERENTIAL SCANNING CALORIMETRY; DOSE RESPONSE; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; HUMAN; LIPID BILAYER; METABOLISM; MOLECULAR GENETICS; PROTEIN SECONDARY STRUCTURE; TIME FACTOR; TUMOR CELL LINE;

AMINO ACID SEQUENCE; APOPTOSIS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; CELLS, CULTURED; CIRCULAR DICHROISM; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LACTOFERRIN; LIPID BILAYERS; MEMBRANE LIPIDS; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHOSPHATIDYLSERINES; PROTEIN STRUCTURE, SECONDARY; TIME FACTORS;

EID: 84941695929     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2015.07.018     Document Type: Article

References (69)

1. D.S. Shewach, and R.D. Kuchta Introduction to cancer chemotherapeutics Chem. Rev. 109 2009 2859 2861
2. D. Schadendorf, M. Worm, B. Algermissen, C.M. Kohlmus, and B.M. Czarnetzki Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity Cancer 73 1994 103 108
3. H. Helmbach, E. Rossmann, M.A. Kern, and D. Schadendorf Drug-resistance in human melanoma Int. J. Cancer 93 2001 617 622
4. F. Hodi, S. Lee, D. McDermott, U. Rao, L. Butterfield, A. Tarhini, and et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial JAMA 312 2014 1744 1753
5. P.M. Black Brain tumors N. Engl. J. Med. 324 1991 1555 1564
6. J. Skog, T. Wurdinger, S. van Rijn, D.H. Meijer, L. Gainche, M. Sena-Esteves, and et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers Nat. Cell Biol. 10 2008 1470 1476
7. S. Riedl, D. Zweytick, and K. Lohner Membrane-active host defense peptides - challenges and perspectives for the development of novel anticancer drugs Chem. Phys. Lipids 164 2011 766 781
8. D.W. Hoskin, and A. Ramamoorthy Studies on anticancer activities of antimicrobial peptides Biochim. Biophys. Acta 1778 2008 357 375
9. J.S. Mader, and D.W. Hoskin Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment Expert Opin. Investig. Drugs 15 2006 933 946
10. F. Schweizer Cationic amphiphilic peptides with cancer-selective toxicity Eur. J. Pharmacol. 625 2009 190 194
11. N. Papo, and Y. Shai Host defense peptides as new weapons in cancer treatment Cell. Mol. Life Sci. 62 2005 784 790
12. S.K. Bhutia, and T.K. Maiti Targeting tumors with peptides from natural sources Trends Biotechnol. 26 2008 210 217
13. S. Riedl, B. Rinner, M. Asslaber, H. Schaider, S. Walzer, A. Novak, and et al. In search of a novel target - phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy Biochim. Biophys. Acta 1808 2011 2638 2645
14. B. Fadnes, O. Rekdal, and L. Uhlin-Hansen The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells BMC Cancer 9 2009 183
15. T. Utsugi, A.J. Schroit, J. Connor, C.D. Bucana, and I.J. Fidler Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes Cancer Res. 51 1991 3062 3066
16. L.V. Rao, J.F. Tait, and A.D. Hoang Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity Thromb. Res. 67 1992 517 531
17. H. Woehlecke, A. Pohl, N. Alder-Baerens, H. Lage, and A. Herrmann Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2) Biochem. J. 376 2003 489 495
18. M. Cichorek, K. Kozlowska, J.M. Witkowski, and M. Zarzeczna Flow cytometric estimation of the plasma membrane diversity of transplantable melanomas, using annexin V Folia Histochem. Cytobiol. 38 2000 41 43
19. D. Zweytick, S. Riedl, B. Rinner, M. Asslaber, H. Schaider, S. Walzer, and et al. In search of new targets - the membrane lipid phosphatidylserine - the underestimated Achilles' heel of cancer cells Ann. Oncol. 22 Suppl. 3 2011 iii42 iii43
20. H. Schröder-Borm, R. Bakalova, and J. Andrä The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine FEBS Lett. 579 2005 6128 6134
21. E.M. Bevers, P. Comfurius, and R.F. Zwaal Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implications Lupus 5 1996 480 487
22. R.F. Zwaal, and A.J. Schroit Pathophysiologic implications of membrane phospholipid asymmetry in blood cells Blood 89 1997 1121 1132
23. E.M. Bevers, P. Comfurius, D.W. Dekkers, M. Harmsma, and R.F. Zwaal Regulatory mechanisms of transmembrane phospholipid distributions and pathophysiological implications of transbilayer lipid scrambling Lupus 7 Suppl. 2 1998 S126 S131
24. M. Seigneuret, and P.F. Devaux ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes Proc. Natl. Acad. Sci. U. S. A. 81 1984 3751 3755
25. C. Kirszberg, L.G. Lima, Da Silva dO, W. Pickering, E. Gray, T.W. Barrowcliffe, and et al. Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines Melanoma Res. 19 2009 301 308
26. J. Connor, C. Bucana, I.J. Fidler, and A.J. Schroit Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer-leaflet lipid by prothrombinase complex formation Proc. Natl. Acad. Sci. U. S. A. 86 1989 3184 3188
27. J.L. Gifford, H.N. Hunter, and H.J. Vogel Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties Cell. Mol. Life Sci. 62 2005 2588 2598
28. D. Zweytick, G. Pabst, P.M. Abuja, A. Jilek, S.E. Blondelle, J. Andrä, and et al. Influence of N-acylation of a peptide derived from human lactoferricin on membrane selectivity Biochim. Biophys. Acta 1758 2006 1426 1435
29. D. Zweytick, S. Tumer, S.E. Blondelle, and K. Lohner Membrane curvature stress and antibacterial activity of lactoferricin derivatives Biochem. Biophys. Res. Commun. 369 2008 395 400
30. D. Zweytick, G. Deutsch, J. Andrä, S.E. Blondelle, E. Vollmer, R. Jerala, and et al. Studies on lactoferricin derived E. coli membrane active peptides reveal differences in the mechanism of N-acylated versus non-acylated peptides J. Biol. Chem. 24 2011 21266 21276
31. S. Riedl, B. Rinner, H. Schaider, K. Lohner, and D. Zweytick Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine BioMetals 27 2014 981 997
32. S.A. Rosenberg, and A.B. Einstein Jr. Sialic acids on the plasma membrane of cultured human lymphoid cells. Chemical aspects and biosynthesis J. Cell Biol. 53 1972 466 473
33. A. Risso, M. Zanetti, and R. Gennaro Cytotoxicity and apoptosis mediated by two peptides of innate immunity Cell. Immunol. 189 1998 107 115
34. L. Whitmore, and B.A. Wallace DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data Nucleic Acids Res. 32 2004 W668 W673
35. L. Whitmore, and B.A. Wallace Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases Biopolymers 89 2008 392 400
36. N. Sreerama, and R.W. Woody Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set Anal. Biochem. 287 2000 252 260
37. G.R. Bartlett Colorimetric assay methods for free and phosphorylated glyceric acids J. Biol. Chem. 234 1959 469 471
38. R.M. Broekhuyse Phospholipids in tissues of the eye. I. Isolation, characterization and quantitative analysis by two-dimensional thin-layer chromatography of diacyl and vinyl-ether phospholipids Biochim. Biophys. Acta 152 1968 307 315
39. W. Jing, E.J. Prenner, H.J. Vogel, A.J. Waring, R.I. Lehrer, and K. Lohner Headgroup structure and fatty acid chain length of the acidic phospholipids modulate the interaction of membrane mimetic vesicles with the antimicrobial peptide protegrin-1 J. Pept. Sci. 11 2005 735 743
40. D. Zweytick, B. Japelj, E. Mileykovskaya, M. Zorko, W. Dowhan, S.E. Blondelle, and et al. N-acylated peptides derived from human lactoferricin perturb organization of cardiolipin and phosphatidylethanolamine in cell membranes and induce defects in Escherichia coli cell division PLoS One 9 2014 e90228
41. M.S. Soengas, P. Capodieci, D. Polsky, J. Mora, M. Esteller, X. Opitz-Araya, and et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma Nature 409 2001 207 211
42. J. Maupetit, P. Derreumaux, and P. Tufféry PEP-FOLD: an online resource for de novo peptide structure prediction Nucleic Acids Res. 37 2009 W498 W503
43. J. Maupetit, P. Derreumaux, and P. Tufféry A fast method for large-scale de novo peptide and miniprotein structure prediction J. Comput. Chem. 31 2010 726 738
44. P. Thévenet, Y. Shen, J. Maupetit, F. Guyon, P. Derreumaux, and P. Tufféry PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides Nucleic Acids Res. 40 2012 W288 W293
45. D.W. Kufe Mucins in cancer: function, prognosis and therapy Nat. Rev. Cancer 9 2009 874 885
46. K.L. Carraway, S.A. Price-Schiavi, X. Zhu, and M. Komatsu Membrane mucins and breast cancer Cancer Control 6 1999 613 614
47. S. Bafna, S. Kaur, and S.K. Batra Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells Oncogene 29 2010 2893 2904
48. M. Belting Heparan sulfate proteoglycan as a plasma membrane carrier Trends Biochem. Sci. 28 2003 145 151
49. S. Ran, and P.E. Thorpe Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy Int. J. Radiat. Oncol. Biol. Phys. 54 2002 1479 1484
50. N. Yang, M.B. Strom, S.M. Mekonnen, J.S. Svendsen, and O. Rekdal The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells J. Pept. Sci. 10 2004 37 46
51. T. Miyashita, and J.C. Reed Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line Blood 81 1993 151 157
52. J.S. Mader, J. Salsman, D.M. Conrad, and D.W. Hoskin Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines Mol. Cancer Ther. 4 2005 612 624
53. Huang Yb, Wang Xf, Wang Hy, Y. Liu, and Y. Chen Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework Mol. Cancer Ther. 10 2011 416 426
54. L.T. Eliassen, B.E. Haug, G. Berge, and O. Rekdal Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications J. Pept. Sci. 9 2003 510 517
55. C. Sinthuvanich, A.S. Veiga, K. Gupta, D. Gaspar, R. Blumenthal, and J.P. Schneider Anticancer β-hairpin peptides: membrane-induced folding triggers activity J. Am. Chem. Soc. 134 2012 6210 6217
56. F.L. Wang, S.X. Cui, L.P. Sun, X.J. Qu, Y.Y. Xie, L. Zhou, and et al. High expression of alpha 2, 3-linked sialic acid residues is associated with the metastatic potential of human gastric cancer Cancer Detect. Prev. 32 2009 437 443
57. A. Litynska, M. Przybylo, E. Pochec, D. Hoja-Lukowicz, D. Ciolczyk, P. Laidler, and et al. Comparison of the lectin-binding pattern in different human melanoma cell lines Melanoma Res. 11 2001 205 212
58. A. Cazet, S. Julien, M. Bobowski, M.A. Krzewinski-Recchi, A. Harduin-Lepers, S. Groux-Degroote, and et al. Consequences of the expression of sialylated antigens in breast cancer Carbohydr. Res. 345 2010 1377 1383
59. R. Sasisekharan, Z. Shriver, G. Venkataraman, and U. Narayanasami Roles of heparan-sulphate glycosaminoglycans in cancer Nat. Rev. Cancer 2 2002 521 528
60. R.D. Sanderson Heparan sulfate proteoglycans in invasion and metastasis Semin. Cell Dev. Biol. 12 2001 89 98
61. D.F. Liu, Z. Shriver, Y.W. Gi, G. Venkataraman, and R. Sasisekharan Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans Semin. Thromb. Hemost. 28 2002 67 78
62. G.W. Yip, M. Smollich, and M. Götte Therapeutic value of glycosaminoglycans in cancer Mol. Cancer Ther. 5 2006 2139 2148
63. M.M. Fuster, and J.D. Esko The sweet and sour of cancer: glycans as novel therapeutic targets Nat. Rev. Cancer 5 2005 526 542
64. A. Wade, A.E. Robinson, J.R. Engler, C. Petritsch, C.D. James, and J.J. Phillips Proteoglycans and their roles in brain cancer FEBS J. 280 2013 2399 2417
65. T.F.C.M. Smetsers, E.M.A. Van de Westerlo, G.B. ten Dam, R. Clarijs, E.M.M. Versteeg, W.L. van Geloof, and et al. Localization and characterization of melanoma-associated glycosaminoglycans: differential expression of chondroitin and heparan sulfate epitopes in melanoma Cancer Res. 63 2003 2965 2970
66. H. Engelberg Plasma heparin levels in normal man Circulation 23 1961 578 581
67. N. Volpi, M. Cusmano, and T. Venturelli Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma Biochim. Biophys. Acta 1243 1995 49 58
68. F. Madani, S. Lindberg, Ü. Langel, S. Futaki, and A. Grälund Mechanisms of cellular uptake of cell-penetrating peptides J. Biophys. 2014 2011
69. M. Zorko, and Ü. Langel Cell-penetrating peptides: mechanism and kinetics of cargo 1delivery Adv. Drug Deliv. Rev. 57 2005 529 545